EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of Bailing capsules combined with sodium glucose cotransporter inhibitors in diabetic kidney disease treatment

Han Li, Fei-Hong Ren, Li-Ping Yang, Hui-Min Mao, Fang Ma, Yu-Yang Wang, Qi Jin, Peng-Yuan Liang, Yong-Li Zhan

World Journal of Diabetes · 15.06.2026 · 17 (6)

DOI: 10.4239/wjd.120131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Diabetes, online erschienen am 15.06.2026. Verfasst von Han Li und 8 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. Integrative approaches combining traditional Chinese medicine and Western pharmacotherapy have shown potential benefits. AIM To evaluate the efficacy and safety of Bailing capsules (BCs) combined with SGLT2is in DKD treatment. METHODS Randomized controlled trials (RCTs) were retrieved from China National Knowledge Infrastructure, Wanfang, VIP, PubMed, Web of Science, EMBASE, and Cochrane Library up to September 14, 2025. Data extraction and quality assessment were performed independently by two reviewers using the Cochrane risk of bias tool. Meta-analysis was conducted with Stata 18.0, and trial sequential analysis (TSA) was applied to assess the robustness of evidence. RESULTS Fourteen RCTs involving 1919 patients were included. Compared with SGLT2is alone, BC plus SGLT2is significantly improved clinical efficacy [relative risk (RR) = 1.157, 95%CI: 1.102-1.216]; reduced fasting blood glucose [weighted mean difference (WMD) = -0.729, 95%CI: -0.976 to -0.482] and glycated hemoglobin (WMD = -0.680, 95%CI: -0.768 to -0.592) levels; altered renal function markers, including serum creatinine [SCr; standardized mean difference (SMD) = -1.033, 95%CI: -1.258 to -0.808], blood urea nitrogen (WMD = -1.158, 95%CI: -1.537 to -0.779), and β2-microglobulin (WMD = -1.237, 95%CI: -1.471 to -1.002) levels; and reduced 24-hour urinary protein levels (SMD = -1.329, 95%CI: -1.801 to -0.857). No significant increase in the incidence of adverse events was observed (RR = 0.939, P = 0.767). Subgroup analysis suggested that the optimal BC dosage was 1.0-3.0 g three times daily. TSA confirmed the reliability of the evidence for a reduction in SCr. CONCLUSION BC combined with SGLT2is appears to be effective and safe for improving glycemic control and renal function in DKD patients. Further high-quality, multicenter RCTs are warranted to validate these findings.

Zitieren

APA

Li, H., Ren, F., Yang, L., Mao, H., Ma, F., Wang, Y., Jin, Q., Liang, P., & Zhan, Y. (2026). Efficacy and safety of Bailing capsules combined with sodium glucose cotransporter inhibitors in diabetic kidney disease treatment. World Journal of Diabetes, 17(6). https://doi.org/10.4239/wjd.120131

Vancouver

Li H, Ren F, Yang L, Mao H, Ma F, Wang Y, et al. Efficacy and safety of Bailing capsules combined with sodium glucose cotransporter inhibitors in diabetic kidney disease treatment. World Journal of Diabetes. 2026;17(6). doi:10.4239/wjd.120131

BibTeX
@article{Li2026,
  author = {Li, Han and Ren, Fei-Hong and Yang, Li-Ping and Mao, Hui-Min and Ma, Fang and Wang, Yu-Yang and Jin, Qi and Liang, Peng-Yuan and Zhan, Yong-Li},
  title = {Efficacy and safety of Bailing capsules combined with sodium glucose cotransporter inhibitors in diabetic kidney disease treatment},
  journal = {World Journal of Diabetes},
  year = {2026},
  volume = {17},
  number = {6},
  doi = {10.4239/wjd.120131}
}
Kostenlos starten →